07/14/2026
Let’s talk about low-dose naltrexone (LDN), a medication we compound often!
LDN is actually a pretty cool medication whose clinical personality changes dramatically with dose. Standard naltrexone is typically used at 50+ mg as an opioid receptor antagonist for alcohol and opioid use disorders. That's not what this is. LDN refers to much smaller doses, commonly in the range of 0.5 to 4.5 mg daily.
At these lower doses, LDN is being used as a *neuroimmune modulator*, with potential effects on glial activation, innate immune signaling, endogenous opioid tone, pain amplification, and inflammatory resilience. This comes in real handy in midlife (men and women), where changing hormone-mediated immune regulation can make inflammatory, mast-cell, post-viral, pain, and sleep patterns more visible.
How does it work?
LDN transiently blocks opioid receptors, and this brief blockade can create a rebound increase in endogenous opioid activity.
These opioid molecules then participate in cytokine signaling, T-cell activity, microglial tone, mast-cell behavior, gut-brain signaling, HPA-axis stress response, sleep continuity, mood regulation, and pain modulation. Remember, the opioid system sits at the intersection of immune signaling, nervous-system reactivity, and inflammatory resilience.
So essentially, what LDN is doing is helping facilitate a better, more adaptive relationship between the immune system and the nervous system.